Johnson & Johnson $JNJ Shares Acquired by Synergy Asset Management LLC

Synergy Asset Management LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 250.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 18,771 shares of the company’s stock after purchasing an additional 13,418 shares during the period. Synergy Asset Management LLC’s holdings in Johnson & Johnson were worth $3,481,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in JNJ. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth $28,000. Evolution Wealth Management Inc. purchased a new position in Johnson & Johnson during the 2nd quarter worth $27,000. Semmax Financial Advisors Inc. lifted its stake in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the period. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at about $35,000. Finally, Signature Resources Capital Management LLC increased its stake in shares of Johnson & Johnson by 262.9% during the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after acquiring an additional 184 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $204.32 on Tuesday. The stock has a fifty day moving average price of $201.45 and a 200 day moving average price of $183.45. The stock has a market cap of $492.26 billion, a PE ratio of 19.72, a P/E/G ratio of 2.13 and a beta of 0.34. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $215.18. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent analyst reports. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Barclays raised their price target on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a report on Tuesday, December 30th. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Scotiabank began coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 target price on the stock. Four analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $212.62.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.